Fig. 3: Improved circulation time, tumor delivery and therapeutic efficacy of VCR/Lipo-SM-CSS-Chol.

a–c Blood kinetics (a), biodistribution (b, at 48 h post i.v. injection) and pharmacokinetic parameters (c) of free VCR and VCR/Lipo in orthotopic MC38 colorectal cancer (CRC) mouse model (n = 3 mice; tumor: ~400 mg) following a single i.v. administration at 2 mg VCR/kg. d–g Therapeutic effects of VCR/Lipo in subcutaneous (s.c.) SU-DHL-4 diffuse large B-cell lymphoma xenograft model (n = 5 mice, tumors: ~200 mm³) in severe combined immunodeficient CB17/Icr-Prkdc^scid/IcrIcoCrl mice i.v. injected once at 2 mg VCR/mg. d Individual tumor growth curve. e Average tumor growth curve. f Mice bearing s.c. lymphoma image taken on day 27. g Kaplan–Meier survival curves. Data in a–c (n = 3 mice), e (n = 5 mice) are expressed as mean ± s.d. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test; survival curves were compared using the log-rank Mantel–Cox test. Source data are provided as a Source Data file.